Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N5/06—Animal cells or tissues; Human cells or tissues
  • C12N5/0602—Vertebrate cells
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N5/06—Animal cells or tissues; Human cells or tissues
  • C12N5/0602—Vertebrate cells
  • C12N5/0618—Cells of the nervous system
  • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N5/0081—Purging biological preparations of unwanted cells
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N5/06—Animal cells or tissues; Human cells or tissues
  • C12N5/0602—Vertebrate cells
  • C12N5/0618—Cells of the nervous system
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N5/06—Animal cells or tissues; Human cells or tissues
  • C12N5/0602—Vertebrate cells
  • C12N5/0618—Cells of the nervous system
  • C12N5/0623—Stem cells
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
  • G01N33/56966—Animal cells

Definitions

• the present invention provides manufacturing methods for a population of mammalian-derived glial restricted progenitor cells (GRPs) with decreased potentially
• an antibody panel to characterize GRPs and a method for its use in characterizing GRP cells is also provided in the present invention.
• Glial restricted progenitor cells are defined by their reactivity with antibody A2B5, which recognizes a subset of c-series gangliosides (Dietrich et al . , Glia 2002 40:65-77; Rao and Mayer-Proschel, Dev. Biol. 1997 188:48-63; Saito et al . , J. Neurochem. 2001 78:64-74; Windrem et al., Nat. Med. 2004 10:93-97).
• GRPs GRPs
• GRPs GRPs
• E-CAM polysialated N-CAM, or PSA-NCAM
• ⁇ - ⁇ tubulin Dietrich et al . , Glia 2002 40:65- 77; Rao and Mayer-Proschel, Dev. Biol. 1997 188:48-63).
• GRPs At the time the GRPs are isolated they have already differentiated endogenously beyond neural stem cells into committed lineage-restricted cells. GRPs have not been observed to induce or produce teratomas .
• a very important category of neuron in the brain and spinal cord comprises those whose axons are ensheathed in myelin. When this myelin sheath is damaged,
• oligodendrocytes whose living processes constitute the insulating myelin layer around neuronal axons, are
• Demyelinated neurons cannot properly conduct signals and eventually will die.
• the shiverer mouse which exhibits defects in
• An aspect of the present invention relates to methods for manufacturing mammalian glial restricted progenitor (GRP) cells.
• GFP mammalian glial restricted progenitor
• Another aspect of the present invention relates to a method for decreasing unintended cellular phenotypes in a GRP cell population and/or decreasing standard deviations in cells of the GRP cell population.
• Another aspect of the present invention relates to an antibody panel for characterizing GRP cells comprising antibodies to c-series gangliosides (using A2B5 antibody) , GFAP, and one or more antibodies selected from the group consisting of Oligl, 01ig2, 01, PDGFR- ⁇ , nestin, NG2, PSA- NCAM, TuJl, Ki-67 and NeuN, and methods for characterizing cells as GRP cells with this panel of antibodies.
• Another aspect of the present invention relates to gene expression profiles useful in characterizing GRP cells.
• Another aspect of the present invention relates to a method for manufacturing mammalian neural cells depleted of A2B5-positive cells.
• Another aspect of the present invention relates to methods for use of these manufactured mammalian GRP cells to generate astrocytes and/or oligodendrocytes .
• Another aspect of the present invention relates to methods for use of these manufactured mammalian GRP cells to increasing re-myelination of neurons in a mammal suffering from a disease, disorder, injury or damage associated with demyelination of neurons .
• Another aspect of the present invention relates to methods for use of these manufactured mammalian GRP cells to reducing glial scar formation.
• Yet another aspect of the present invention relates to methods for use of these manufactured mammalian GRP cells in the treatment of neurodegenerative diseases or disorders or damage or injury to the nervous system or a portion thereof in mammals.
• Figures 1A, IB and 1C show pilot scale growth curves of three independent cell preparations manufactured in accordance with the present invention.
• Figures 2A and 2B show production-scale growth curves of cells manufactured in accordance with the present inventio .
• Figures 3A and 3B show a comparison of cell viability on suspension versus poly-L-ornithine treated surfaces
• the present invention provides methods for
• GRPs mammalian glial progenitor cells
• GRPs are also referred to as glial restricted precursor cells or glial progenitor cells in the literature.
• Mammalian GRP cells of the present invention can be derived from any mammalian tissue source capable of
• mammalian tissue sources include, without limitation, embryonic/fetal, and adult (inclusive of all ages after birth) sources, all from tissues including, but not limited to neural, brain, spinal cord, optic nerve, olfactory epithelium, endocrine, skin, muscle, fat, connective, placental, cord blood, blood, bone marrow, bone, embryonic stem cells, and induced pluripotent cells.
• A2B5 positive cells By capable of generating A2B5 positive cells it is meant to include mammalian tissue sources differentiated into A2B5 positive cells, mammalian tissue sources de-differentiated into A2B5 positive cells, as well as mammalian tissue sources de-differentiated and then differentiated into A2B5 positive cells.
• Mammalian glial restricted progenitor (GRP) cells are manufactured in accordance with the present invention by isolating A2B5 antibody-reactive cells from a mammalian tissue source capable of generating A2B5 positive cells.
• the A2B5-positive cells are then cultured for greater than 6 days in vitro (DIV) on a substrate.
• the cultured cells are then harvested.
• the method comprises dissociating mammalian neural tissue such as, but not limited to, fetal cadaver forebrain tissue, fetal cadaver spinal cord tissue, mammalian biopsy brain or spinal cord tissue, or the like into a cell suspension.
• the mammalian neural tissue is obtained after neural tube closure.
• neural tissue obtained after neural tube closure at, for example about 14 to about 24 gestational week tissues as been demonstrated to yield consistent product.
• Dissociation is performed either enzymatically, mechanically, or both enzymatically and mechanically in accordance with known methods.
• A2B5 antibody-reactive cells can be isolated be various means known to those of skill in the art.
• the A2B5 antibody-reactive cells are isolated using magnetic activated cell sorting.
• cells can be passed over a column after a single A2B5 antibody labeling using iltenyi magnetic bead
• antibody positive cells can be captured using fluorescence activated cell sorting or immunopanning via standard methods.
• the column or FACS or immunopanning dishes) enriches for A2B5 (+) cells and reduces A2B5(-) cells.
• the A2B5-positive population is then cultured for greater than 6 days in vitro (DIV) , for example
• This manufacturing process differs from previously described manufacturing processes in that a method of sorting desired cells with a single antibody is used and the growth is extended from 6-DIV with no passaging to growth for up to two passages or greater than 6-DIV, for example approximately 10-20-DIV, 15-20 DIV, at least 20 DIV, or up to 100 DIV or greater. Further, cells are grown not in suspension but rather on a substrate for adherence of cells.
• substrates include, but are not limited to, poly-L-ornithine , poly-L-lysine and recombinant or natural extracellular matrix molecules or fragments thereof, such as, but not limited to laminin, fibronectin and CELLstartTM (xeno-free substrate for attachment and expansion of human embryonic, mesenchymal, and neural stem cells, Invitrogen Corporation, Carlsbad, CA) .
• Growth curves, yields, and immunologically defined phenotypes of cells manufactured in accordance with the method of the present invention exhibit tightened variability and decreased unintended cellular phenotypes without altering their therapeutic ability.
• Phase contrast microscopy revealed a stable morphological phenotype prior to the first passage (6-DIV) at the end of the second passage (20-DIV; harvest) and up to 100 days in vitro. This bi- to multi-polar morphology is consistent across preparations with three independent cell preparations .
• Pilot scale growth curves of cells manufactured in accordance with the present invention are depicted in Figure 1A through 1C.
• Three independent cell preparations are shown in Figures 1A, IB and 1C, respectively, as is a comparison of growth on untreated plastic ("suspension") and growth on poly-L-ornithine treated tissue culture plastic.
• Cell preparations grown on substrate-coated flasks exhibited increased slope and increased plating efficiency.
• Production-scale growth curves are depicted in Figures 2A and 2B. These curves are similar to the pilot scale and demonstrate the cells harvested at 20-DIV are not nearing senescence.
• Cells manufactured in accordance with the present invention were immunophenotyped using a panel of antibodies which recognize desired phenotypes (glial restricted progenitors and their progeny) as well as potential contaminating unintended cellular phenotypes (neuronal progenitors, neurons, microglia and endothelial cells) .
• Antibodies in this panel are chosen from A2B5, GFAP, PDGFR- a, Oligl, 01ig2, 01, nestin, NG2, PSA-NCAM, TuJl, Ki-67 and/or NeuN.
• Immunophenotyping with this unique panel of antibodies showed a decrease in potentially unintended cellular phenotypes (PSA-NCAM and TuJl) at greater than 6- DIV versus 6-DIV, as well as a decrease in the standard deviations in cells produced in accordance with the method of the present invention.
• another aspect of the present invention relates to a method for decreasing potentially unintended cellular phenotypes in a GRP cell population and/or decreasing standard deviations in cells of the GRP cell population which comprises harvesting cells for greater than 6-DIV.
• the decrease in potentially unintended cellular phenotypes and/or decrease in standard deviations in cells is determined by comparison to cells harvested at 6-DIV. It has also been found that freezing and thawing of a GRP cell population further decreases unintended phenotype. While the desirable ⁇ 2 ⁇ 5, GFAP and Ki-67 positive phenotypes are retained upon freeze/thaw, the markers for unintended cellular phenotypes (PSA-NCAM and TuJl) are reduced by >50%.
• another aspect of the present invention relates to a method for decreasing potentially unintended cellular phenotypes in a GRP cell population which comprises freezing and thawing the GRP cell population.
• the GRP cell population is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoe
• the GRP cell population is manufactured by a method wherein A2B5-positive cells are cultured for 6 DIV or less. The cultured cells are then harvested and frozen. After thawing, the cells can be cultured for 3 or more additional days in vitro (DIV) to increase cell number.
• DIV in vitro
• immunophenotyping with this selected panel of antibodies provides a useful reliable means to characterize this cellular therapeutic.
• another aspect of the present invention relates to this antibody panel for characterizing GRP cells comprising A2B5, GFAP, and one or more antibodies selected from the group consisting of Oligl, 01ig2, 01, PDGFR-oi, nestin, NG2 , PSA-NCAM, TuJl, Ki-67 and NeuN and methods for characterizing cells as GRP cells and/or documenting the purity of the cell population with this panel of antibodies.
• cells are characterized using the antibody panel by first plating the cells according to standard protocols on coverslips or in multichamber slides or the like, allowed to grow overnight under standard tissue culture conditions, and then fixed and stained according to standard procedures. Immunopositive cells are identified using standard microscopy methods, and the percentages of cells positive for each antibody are defined relative to the total number of cells (as defined by a pan nuclei stain: DAPI or the like) .
• the following immuriophenotype using this antibody panel is indicative of a population of mammalian cells being GRPs : a majority of cells are positive for A2B5 and one or more of GFAP, nestin, NG2, PDGFR- , Oligl, 01ig2 and 01 and a majority of cells are negative for one or more of PSA-NCA , TUJ1, PECA , CD68, and NeuN.
• major as used herein it is meant that greater than 50% of the cells are positive or negative for the selected antibody.
• gene targets In addition to immunocytochemical characterization of the cellular product, gene targets whose expression
• Gene expression data were collected from unpurified cells, GRP cells harvested at 6-DIV originating from 15 brain tissues and GRP cells produced in accordance with the method of the present invention. Approximately 375 genes showed at least 5-fold changes in expression level (increasing and
• gene expression profiles may be generated and evaluated via techniques such as chip/array analysis, multiplex RT-PCR and qPCR as a means for identifying cell populations.
• A2B5 antibody-reactive cells are isolated from a mammalian tissue source capable of generating A2B5 positive cells. Cells that remain after removing the A2B5 antibody-reactive cells are then
• the cells are cultured for one or more days in vitro (DIV) on a substrate.
• the collected cells may optionally be further depleted of certain cell types by freezing and thawing the cell population.
• Another aspect of the present invention relates to method for generating astrocytes and/or oligodendrocytes from the GRPs manufactured in accordance with the present invention.
• the GRP cells manufactured in accordance with the present invention are cultured under conditions which promote differentiation to astrocytes and/or oligodendrocytes.
• the GRP cells are cultured under conditions which promote differentiation to astrocytes. Two nonlimiting examples of media
• formulations that promote astrocyte differentiation include: 1) growth of GRPs in DME /F12, Nl or N2 supplement, basic FGF, BMP4 with these growth factors present in the ng/mL range or the 10-100 ng/mL range; and 2) D E /F12, Nl or N2 supplement, 1-10% FBS, and basic FGF in the ng/mL range or the 10-100 ng/mL range.
• the GRP cells are cultured under conditions which promote
• Two nonlimiting examples of media formulations and conditions that promote oligodendrocyte differentiation include: 1) growth of GRPs in DMEM/F12 medium lacking growth factors for two days, and transfer of cells to a DME /F12 medium supplemented with N2, PDGF-AA present in the ng/mL range or the 10-100 ng/mL range, and T3 in the 1-100 nM range; and 2) growth of GRPs in D E /F12 medium supplemented with N2, T3 in the 100' s of nM range, N-acetyl cysteine in the tens of g/mL range, and PDGF-AA and CNTF in the ng/mL range or the 10-100 ng/mL range .
• GRPs manufactured in accordance with the method of the present invention successfully integrate, differentiate into oligodendrocytes and astrocytes, and remyelinate axons in demyelinated neural tissue of the brain and spinal cord.
• the present invention also relates to methods for using GRP cells manufactured in accordance with the present invention to produce astrocytes and oligodendrocytes in vivo in mammals and to increase re-myelination of neurons in a mammal suffering from a disease, disorder, injury or damage associated with demyelination of neurons.
• GRP cells manufactured in accordance with the present invention to produce astrocytes and oligodendrocytes in vivo in mammals and to increase re-myelination of neurons in a mammal suffering from a disease, disorder, injury or damage associated with demyelination of neurons.
• Between 0.01 and 100 million cells can be administered by direct parenchymal transplantation using catheters or needles familiar to neurosurgeons skilled in the art, involving one or more injections. These transplantations can be performed after accessing the neural tissue directly by the use of a burr hole or laminectomy.
• the transplants can be performed into the spinal cord by CT-guided percutaneous delivery without the need for direct visual access of the neural target tissue by an interventional radiologist skilled in the art.
• cells can be administered to the cerebrospinal fluid (CSF) such as via lumbar puncture or other suitable methods rather than directly into the parenchyma.
• CSF cerebrospinal fluid
• Cells can also be administered by intravenous administration for certain diseases.
• CSF cerebrospinal fluid
• several clinical trials with other neural cell types are currently being conducted for these diseases. Similar protocols and procedures used in these clinical trials with other neural cells can be adapted routinely by those of skill in the art for use with the GRPs manufactured in accordance with the present invention.
• the shiverer mouse possesses an autosomal recessive mutation that results in the failure of these mice to develop myelin basic protein (BP) .
• Endogenous oligodendrocytes formed in the CNS of shiverer mice fail to assemble compacted myelin (Privat et al . , Neurosci. Lett. 1979 12:107-112).
• a shiverer mouse strain that also carries an autosomal recessive mutation in the Rag2 gene which encodes a protein essential to the generation of mature B and T lymphocytes and therefore displays cell- mediated immune deficiencies was developed (Shinkai et al . Cell 1992 68:855-867).
• mice were implanted with 100,000 human GRPs at a single site targeting the
• mice The differentiation potential of human GRPs in vivo was assessed immunocytochemically in brain sections from these mice.
• One group of mice was sacrificed at eight weeks post- implantation while another group was sacrificed for humane reasons at a time when neurological deterioration resulted in markedly impaired ambulation and frequent episodes of sustained seizures (typically 12- to 18-weeks postnatal) .
• Brain sections were stained with anti-myelin basic protein (BP; expression of intact MBP recognized by this antibody is not observed in shiverer mice, thus, expression of MBP is solely from implanted human GRPs) and anti-human GFAP antibodies (which does not recognize murine GFAP) .
• BP anti-myelin basic protein
• Laminectomies were performed at the thoracic level (T8-T9) and each animal received a single injection of approximately 150,000 human GRPs in 2- L of saline into the dorsal column. Animals were implanted with human GRPs at two or seven days post-disease symptoms. Animals were sacrificed at one week, two weeks, and four weeks post-implantation.
• Engrafted human GRP cells were detected using HuNA antibody in 40- ⁇ transverse sections of spinal cord near the implant site.
• 0X42 antibody was used to detect CDllb on the surface of host activated microglia which are present during an inflammatory response.
• Hematoxylin and eosin (H&E) staining was used to determine macrophage and microglia infiltration.
• HuNA staining closely localized to immunostaining with 0X42 one week post-transplantation. Pronounced H&E staining around the injection site is also indicative of host infiltration of macrophage and microglia. By two weeks posttransplantation, HuNA co-localization with 0X42
• Transplanted human GRPs were able to survive in the DA/EAE rat spinal cord up to twelve weeks, the longest time point assessed, following injection at both two days and seven days post- disease initiation. Thus, human GRPs are able to survive under conditions that mimic those found in inflammatory lesions of human multiple sclerosis.
• Glial cells have been shown to play important roles in the pathogenesis of the neurodegenerative disease Amyotrophic Lateral Sclerosis (ALS) (Howland et al . PNAS 99, 1105, 1995; Clement et al . Science 302, 113, 2003; Rothstein et al . Ann. Neurol. 38, 73, 1995) .
• Astrocytes play many important functions in the CNS, including cerebrovascular regulation, modulation of synaptic transmission (e.g. glutamate transport) as well as other effects including release of growth factors and provision of trophic support for neurons as well as glia. Glial cells may also reduce or prevent formation of reactive astrocytes, which cause deleterious effects in many
• neurodegenerative diseases and glial cells may reduce levels of glial scarring such as occurs in spinal cord injury and several neurodegenerative diseases. Furthermore, transplantation of normal glial cells, which subsequently differentiated into astrocytes, into a rat model of ALS has been demonstrated to be neuroprotective in this model
• glial progenitor cell therapy will be of benefit in other neurodegenerative diseases or disorders including but not limited to Parkinson's, Alzheimer's, Huntington's, and Alexander diseases ( aragakis and
• Another aspect of the present invention relates to methods for use of mammalian GRP cells
• glial cell related neurodegenerative diseases or disorders in mammals as well as injuries or damage to the nervous system or a portion thereof.
• injury or damage it is meant to include damage or injury induced by any cause including, but not limited to, trauma, drugs, radiation, and immune-mediated damage or injury.
• cells of the present invention will be useful in treating neurodegenerative diseases or disorders as well as injuries to the nervous system in mammals not specifically glial cell related.
• between one and 100 million cells manufactured in accordance with the present invention can be administered by direct parenchymal transplantation using catheters or needles familiar to neurosurgeons skilled in the art.
• transplantations can be performed after accessing the neural tissue directly by the use of a burr hole or laminectomy.
• the transplants can be performed into the spinal cord by CT-guided percutaneous deliver without the need for direct visual access of the neural target tissue by an interventional radiologist skilled in the art.
• cells can be administered to the CSF via lumbar puncture rather than directly into the parenchyma.
• Similar protocols and procedures used in these clinical trials with other neural cells can be adapted routinely by those of skill in the art for use with the GRPs manufactured in accordance with the present invention.

Landscapes

• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Life Sciences & Earth Sciences (AREA)
• Biomedical Technology (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biotechnology (AREA)
• Zoology (AREA)
• Genetics & Genomics (AREA)
• Wood Science & Technology (AREA)
• General Health & Medical Sciences (AREA)
• Cell Biology (AREA)
• Biochemistry (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Microbiology (AREA)
• General Engineering & Computer Science (AREA)
• Medicinal Chemistry (AREA)
• Immunology (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Molecular Biology (AREA)
• Veterinary Medicine (AREA)
• Developmental Biology & Embryology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Urology & Nephrology (AREA)
• Hematology (AREA)
• Virology (AREA)
• Epidemiology (AREA)
• Analytical Chemistry (AREA)
• Psychiatry (AREA)
• Hospice & Palliative Care (AREA)
• Tropical Medicine & Parasitology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biophysics (AREA)
• Food Science & Technology (AREA)

Priority Applications (12)

Applications Claiming Priority (4)

Related Child Applications (2)

Publications (1)

Family

ID=43991980

Family Applications (1)

Country Status (11)

Cited By (1)

Families Citing this family (9)

Citations (2)

Family Cites Families (4)

• 2010
  • 2010-11-09 JP JP2012538881A patent/JP5952737B2/ja active Active
  • 2010-11-09 EP EP17188092.5A patent/EP3269803A3/en not_active Withdrawn
  • 2010-11-09 WO PCT/US2010/055956 patent/WO2011059952A1/en not_active Ceased
  • 2010-11-09 EP EP10830580.6A patent/EP2499238B1/en active Active
  • 2010-11-09 CN CN201080051269.2A patent/CN102686721B/zh active Active
  • 2010-11-09 AU AU2010319680A patent/AU2010319680B2/en active Active
  • 2010-11-09 PL PL10830580T patent/PL2499238T3/pl unknown
  • 2010-11-09 NO NO10830580A patent/NO2499238T3/no unknown
  • 2010-11-09 US US13/508,803 patent/US10351823B2/en active Active
  • 2010-11-09 ES ES10830580.6T patent/ES2649396T3/es active Active
  • 2010-11-09 DK DK10830580.6T patent/DK2499238T3/en active
  • 2010-11-09 CN CN201610055313.6A patent/CN105602889A/zh active Pending
  • 2010-11-09 CA CA2780541A patent/CA2780541C/en active Active
• 2016
  • 2016-02-15 JP JP2016026441A patent/JP6346629B2/ja active Active
• 2018
  • 2018-09-19 US US16/135,626 patent/US20190032010A1/en not_active Abandoned

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events